The healthcare sector has been especially weak throughout much of this year, dragged down primarily by biotechnology firms. In an environment of fear and a global market sell-off this is no surprise as biotechs are one of the riskier areas to invest in and were trading well above their earnings (many have very high PE ratios). […]